• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Janssen Highlights Continued Commitment to Cardiovascular & Metabolic Healthcare Solutions with Late-Breaking Data at the First Fully Virtual American College of Cardiology Scientific Session
RARITAN, N.J., March 20, 2020 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that it will unveil late-breaking data from its leading cardiovascular and metabolism portfolio during the virtual American College of Cardiology’s 69th Annual Scientific Session together with the World Congress of Cardiology (ACC.20/WCC) on March 28-30, 2020. Notably, four late-breaking abstracts for XARELTO® (rivaroxaban) will be presented, including data from the Phase 3 VOYAGER PAD study in patients with symptomatic peripheral artery disease (PAD) after lower-extremity revascularization.Click to Tweet: Jan...
Source: Johnson and Johnson - March 20, 2020 Category: Pharmaceuticals Source Type: news

Nursing Home Residents with Seizure Disorders/Epilepsy: Prevalence, Characteristics, and Treatment Patterns (P1.080)
Conclusions: NHRs with seizure disorder/epilepsy have substantial physical and cognitive impairment. Nearly half were prescribed combination AED therapy, and >20[percnt] took 蠅3 different AEDs, suggesting refractory epilepsy. Additional research is needed to assess treatment outcomes and further define optimal care in this population.Disclosure: Dr. Zarowitz has nothing to disclose. Dr. Allen has nothing to disclose. Dr. OShea has nothing to disclose. Dr. Wang has nothing to disclose. Dr. Semenchuk has nothing to disclose. Dr. Barghout has nothing to disclose.
Source: Neurology - April 3, 2016 Category: Neurology Authors: Zarowitz, B., Allen, C., OShea, T., Wang, Z., Semenchuk, M., Barghout, V. Tags: Epilepsy/Clinical Neurophysiology: Geriatric Epilepsy, Epidemiology, and Health Services Source Type: research